Cisplatin-based chemotherapy dramatically boosts survival in invasive cervical cancer

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 1999年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：308 / 309
页数：2
相关论文
共 50 条
  • [21] Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy
    Galsky, Matt D.
    Krege, Susanne
    Lin, Chia-Chi
    Hahn, Noah M.
    Ecke, Thorsten
    Moshier, Erin L.
    Sonpavde, Guru
    Godbold, James H.
    Oh, William K.
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
    M B Polee
    W C J Hop
    T C Kok
    F A L M Eskens
    M E L van der Burg
    T A W Splinter
    P D Siersema
    H W Tilanus
    G Stoter
    A van der Gaast
    British Journal of Cancer, 2003, 89 : 2045 - 2050
  • [23] Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis
    Li, Gang
    Niu, Hui-min
    Wu, Hong-tao
    Lei, Bao-yu
    Wang, Xiao-hua
    Guo, Xiao-bo
    Feng, Shu-lin
    CLINICAL AND INVESTIGATIVE MEDICINE, 2017, 40 (02): : E81 - E94
  • [24] Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy
    Apolo, Andrea B.
    Ostrovnaya, Irina
    Halabi, Susan
    Iasonos, Alexia
    Philips, George K.
    Rosenberg, Jonathan E.
    Riches, Jamie
    Small, Eric J.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (07): : 499 - 503
  • [25] Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
    Polee, MB
    Hop, WCJ
    Kok, TC
    Eskens, FALM
    van der Burg, MEL
    Splinter, TAW
    Siersema, PD
    Tillanus, HW
    Stoter, G
    van der Gaast, A
    BRITISH JOURNAL OF CANCER, 2003, 89 (11) : 2045 - 2050
  • [26] Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer
    Yen, MS
    Juang, CM
    Lai, CR
    Chao, GC
    Ng, HT
    Yuan, CC
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2001, 72 (01) : 55 - 60
  • [27] Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).
    Miron, Benjamin
    Ross, Eric A.
    Anari, Fern
    O'Neill, John
    Hoffman-Censits, Jean H.
    Zibelman, Matthew R.
    Kutikov, Alexander
    Viterbo, Rosalia
    Greenberg, Richard E.
    Chen, David
    Lallas, Costas D.
    Trabulsi, Edouard John
    Alpaugh, R. Katherine
    Dulaimi, Essel
    Golemis, Erica
    Uzzo, Robert
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer
    Agarwal, Archana
    Sonpavde, Guru
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 : S254 - S256
  • [29] ACCELERATED CISPLATIN-BASED CHEMOTHERAPY FOR ADVANCED BLADDER-CANCER
    BOSHOFF, C
    OLIVER, RTD
    GALLAGHER, CJ
    ONG, J
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (10) : 1633 - 1636
  • [30] Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer
    Khrunin, Andrey V.
    Khokhrin, Denis V.
    Moisseev, Alexey A.
    Gorbunova, Vera A.
    Limborska, Svetlana A.
    PHARMACOGENOMICS, 2014, 15 (03) : 329 - 337
12345